– UK, Nottingham – Oncimmune Holdings plc (LON: ONC), a leading global immunodiagnostics group, today announced the appointment of Board member Alistair Macdonald as Non-executive Chair, effective immediately, succeeding Meinhard Schmidt who has retired from the Board.
“Having re-directed our proprietary technology platform towards best-in-class autoantibody profiling services for the pharmaceutical sector, it is gratifying to welcome Alistair with his track record of successfully growing services companies in this sector. Autoantibodies are increasingly recognised as an important part of the toolkit for understanding the effect of and predicted response to immune-modulating therapies. Together with Alistair, I look forward to evaluating acquisition opportunities with the potential to add capabilities and accelerate growth.” said CEO, Dr Adam Hill.
About Alistair Macdonald
Alistair Macdonald brings a wealth of knowledge in the pharma services sector, developed through his 25-year career in life sciences, culminating in his role as CEO of leading, integrated CRO Syneos Health Inc. (Nasdaq: SYNH), which he held for 6 years, before which he was CEO of INC Research which merged with inVentiv Health to become Syneos in 2017. During his time with INC and then Syneos, revenue grew from $20m to over $5.0bn. Before becoming a CEO, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services. Over the last 25 years, he has held management positions in the pharmaceutical industry across manufacturing, consultancy, business and corporate development, data management, and clinical operations.
Alistair Macdonald retired as CEO of Syneos Health in April 2022, a company that he led post-merger through further substantial organic as well as inorganic growth. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialization timelines. Until recently, Alistair has also served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years.
Alistair Macdonald said: “Oncimmune has successfully delivered on its strategy to transform the business from one wholly focussed on a single asset diagnostic to an emerging pharma services business; the foundation stone is now laid for growth. I am excited to bring my knowledge of growing pharma services businesses to help Oncimmune’s experienced senior management team to develop the Company into a leading, global provider of services to the pharmaceutical sector.”
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune’s technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling the development of targeted and more effective treatments.
Oncimmune’s ImmunoINSIGHTS service business is based at the Company’s discovery research center in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
EarlyCDT Product Business
Oncimmune’s immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use is supported by peer-reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.
Oncimmune’s diagnostic products business is located at its laboratory facility in Nottingham, UK.
For more information: https://www.oncimmune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.